A5103494527- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- HIV/AIDS drug development and treatment
- Cancer-related molecular mechanisms research
- RNA modifications and cancer
- Brucella: diagnosis, epidemiology, treatment
- Melanoma and MAPK Pathways
- interferon and immune responses
- Asthma and respiratory diseases
- Liver Disease and Transplantation
- Macrophage Migration Inhibitory Factor
- Monoclonal and Polyclonal Antibodies Research
- Allergic Rhinitis and Sensitization
- Flavonoids in Medical Research
- Dermatology and Skin Diseases
- Computational Drug Discovery Methods
- Hepatitis Viruses Studies and Epidemiology
Sichuan University of Arts and Science
2024-2025
Science and Technology Department of Sichuan Province
2025
Wuhan University
2017
State Key Laboratory of Virology
2017
Third People's Hospital of Yunnan Province
2014
Background: Melanoma is a highly invasive and metastatic malignant tumor, with pathogenesis involving multiple signaling pathways transcription factors. Current treatments face significant challenges, including drug resistance, toxic side effects, recurrence. Purpose: This review aims to evaluate the therapeutic potential of natural products in treatment melanoma identify associated challenges future research opportunities. Methods: A comprehensive literature search was conducted using...
Background: Hepatitis B virus (HBV) infection is a serious health problem worldwide. The pathogenesis of persistent viral and hepatitis very complex. Both factors, as well the host immune response, have been implicated in clinical outcome HBV infection. But mechanism has not clarified. We aimed to investigate levels macrophage migration inhibitory factor (MIF), transforming growth factor-β (TGF-β), interleukin-17 (IL-17) interleukin-10 (IL-10) their correlation with liver disease replication...
Background: Chronic hepatitis B is a serious health problem worldwide with substantial minority of patients experiencing premature death due to end-stage liver disease and/or hepatocelluar carcinoma. Antiviral therapy may help prevent complications chronic B, and seven agents are currently approved in many countries. Of these agents, five nucleos(t)ide analogs that all have risk antiviral drug resistance long-term use. Entecavir treatment has significantly improved the outcome virus (HBV)...
Background: Since the introduction of nucleos(t)ide analogues (NUCs), there has been marked improvement in care patients with chronic hepatitis B, resulting increased survival. Adefovir dipivoxil (ADV) shown efficacy and safety a broad range populations B over 48 to 96 weeks. This study reports 192-week long-term data ADV treatment nucleoside-naive HBeAg-positive B. Methods & Materials: Ninety-eight who had never received nucleoside ADV10 mg/d therapy. All serum level HBV load 105copies/ml...
Background: Hepatitis B virus (HBV) and hepatitis C (HCV) infections are among the most common causes of advanced chronic liver disease worldwide. HBV/HCV co-infection is not uncommon patients with have an increased risk cirrhosis, hepatocellular carcinoma (HCC), even death. The combination pegylated interferon (Peg-IFN) plus ribavirin (RBV) current standard care for naïve patients, achieving a high sustained virological response (SVR) rate. aim present study to explore clinical...
Background: Long-term treatment with nucleos(t)ide analogues (NUCs) is highly effective but HBeAg seroconversion and HBsAg loss are very rare unsatisfied event in CHB patients high viral load and, the resistance mutation relapse rates block benefit from antiviral as well. The aim of present study to evaluate efficacy safety a new therapeutic strategy initial combining Lamivudine(LAM) Adefovir dipivoxil(ADV) HBeAg-positive chronic hepatitis B(CHB). Methods & Materials: One hundred Eighty-two...